These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 23460921)
1. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921 [TBL] [Abstract][Full Text] [Related]
2. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258 [TBL] [Abstract][Full Text] [Related]
3. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of Awasthi N; Schwarz MA; Zhang C; Schwarz RE Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402 [TBL] [Abstract][Full Text] [Related]
5. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884 [TBL] [Abstract][Full Text] [Related]
6. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis. Cheng X; Yang F; Wang Y; Nie W; Mahendra Upadhyay A; Zhang M; Wang Q; Yan Z Can J Gastroenterol Hepatol; 2022; 2022():6015877. PubMed ID: 35719323 [TBL] [Abstract][Full Text] [Related]
7. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429 [TBL] [Abstract][Full Text] [Related]
8. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models. Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068 [TBL] [Abstract][Full Text] [Related]
9. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898 [TBL] [Abstract][Full Text] [Related]
10. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738 [TBL] [Abstract][Full Text] [Related]
11. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504 [TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157 [TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978 [TBL] [Abstract][Full Text] [Related]
14. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144 [TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067 [TBL] [Abstract][Full Text] [Related]
16. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Xiong J; Han S; Ding S; He J; Zhang H Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489 [TBL] [Abstract][Full Text] [Related]
17. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909 [TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]